US OptionsDetailed Quotes
AZN240816P75000
- 0.04
- +0.02+100.00%
15min DelayClose Aug 13 15:59 ET
0.04High0.03Low
0.04Open0.02Pre Close17 Volume1.37K Open Interest75.00Strike Price65.00Turnover63.40%IV10.09%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type-0.0233Delta0.0122Gamma2084.25Leverage Ratio-0.0329Theta-0.0001Rho-48.49Eff Leverage0.0039Vega
AstraZeneca Stock Discussion
Sign in to post a comment
$LumiraDx (LMDXF.US)$ I think whatever $ROCHE HOLDING AG (RHHBY.US)$ intends to do is going to be massive. Owning 75% or more of the company float means at the bare minimum if this were say a 50B deal Roche would only essentially lose out maximum 10B. I'm just thinking to myself if the other pharmas $AstraZeneca (AZN.US)$ & the other one got a piece of this 🥧 too.
4
2
$AstraZeneca (AZN.US)$ you can do better~
AstraZeneca for the second quarter reported total revenue of $12.938 billion, which increased by 13% on a Year-on-Year (YoY) basis. Moreover, On a half-year basis, total Revenue was up by 18% YoY, which stood at $25.617 billion. The revenue growth was driven by an 18% increase in Product Sales and continued growth in Alliance Revenue from partnered medicines.
On a segment basis, total revenue growth from Oncology, cardiovascular, renal and metabolism (CVRM), ...
On a segment basis, total revenue growth from Oncology, cardiovascular, renal and metabolism (CVRM), ...
3
$AstraZeneca (AZN.US)$
AdCom for IMFINZI (durvalumab) tomorrow 7/25 🗓️
» IMFINZI + platinum-containing chemo
» as Tx for non-small cell lung cancer (NSCLC)
Briefing docs for Thursday’s AdCom posted yesterday…
⚠️ FDA highlights concerns about Imfinzi for perioperative NSCLC:
» overtreatment risk
» uncertainty on treatment benefit
» inadequate trial design
» lack of overall survival benefit
» potential for unnecessary exposure
⏰ Meeting begins Thursday, 9 a.m. ET.
AdCom for IMFINZI (durvalumab) tomorrow 7/25 🗓️
» IMFINZI + platinum-containing chemo
» as Tx for non-small cell lung cancer (NSCLC)
Briefing docs for Thursday’s AdCom posted yesterday…
⚠️ FDA highlights concerns about Imfinzi for perioperative NSCLC:
» overtreatment risk
» uncertainty on treatment benefit
» inadequate trial design
» lack of overall survival benefit
» potential for unnecessary exposure
⏰ Meeting begins Thursday, 9 a.m. ET.
3
$AstraZeneca (AZN.US)$ : AdCom 🤔
⇨ Imfinzi + chemotherapy
‣ Neoadjuvant treatment NSCLC
‣ AdCom: 7/25/24 (sBLA)
$BeiGene (BGNE.US)$ : 🤔
⇨ TEVIMBRA (tislelizumab)
‣ Esophageal squamous-cell carcinomas (1L)
‣ PDUFA: July 2024 (sBLA)
⇨ Imfinzi + chemotherapy
‣ Neoadjuvant treatment NSCLC
‣ AdCom: 7/25/24 (sBLA)
$BeiGene (BGNE.US)$ : 🤔
⇨ TEVIMBRA (tislelizumab)
‣ Esophageal squamous-cell carcinomas (1L)
‣ PDUFA: July 2024 (sBLA)
3
$AstraZeneca (AZN.US)$ Time for another ATH
Don't miss out! 🎯👇
$Phathom Pharmaceuticals (PHAT.US)$ : 🤔
⇨ VOQUEZNA® (vonoprazan)
‣ Non-Erosive GERD
‣ PDUFA: 7/19/24 (NDA)
$AstraZeneca (AZN.US)$ : AdCom 🤔
⇨ Imfinzi + chemotherapy
‣ Neoadjuvant treatment NSCLC
‣ AdCom: 7/25/24(sBLA)
$BeiGene (BGNE.US)$ : 🤔
⇨ TEVIMBRA (tislelizumab)
‣ Esophageal squamous-cell carcinomas
‣ PDUFA: July 2024 (BLA)
$Phathom Pharmaceuticals (PHAT.US)$ : 🤔
⇨ VOQUEZNA® (vonoprazan)
‣ Non-Erosive GERD
‣ PDUFA: 7/19/24 (NDA)
$AstraZeneca (AZN.US)$ : AdCom 🤔
⇨ Imfinzi + chemotherapy
‣ Neoadjuvant treatment NSCLC
‣ AdCom: 7/25/24(sBLA)
$BeiGene (BGNE.US)$ : 🤔
⇨ TEVIMBRA (tislelizumab)
‣ Esophageal squamous-cell carcinomas
‣ PDUFA: July 2024 (BLA)
5
1 PDUFA this week! 🔥
$Arcutis Biotherapeutics (ARQT.US)$ : pending decision 🤔
⇨ ARQ-151 topical roflumilast cream
‣ Atopic Dermatitis (aged 6 & older children)
‣ PDUFA date: 7/7/24 (sNDA)
Upcoming PDUFAs & AdCom in July: 📅👇
$Phathom Pharmaceuticals (PHAT.US)$ : 🤔
⇨ VOQUEZNA® (vonoprazan)
‣ Non-Erosive GERD
‣ PDUFA date: 7/19/24 (NDA)
$AstraZeneca (AZN.US)$ : AdCom 🤔
⇨ Imfinzi + chemotherapy
‣ Neoadjuvant treatment NSCLC
‣ AdCom date: 7/25/24(sBLA)
$BeiGene (BGNE.US)$ :...
$Arcutis Biotherapeutics (ARQT.US)$ : pending decision 🤔
⇨ ARQ-151 topical roflumilast cream
‣ Atopic Dermatitis (aged 6 & older children)
‣ PDUFA date: 7/7/24 (sNDA)
Upcoming PDUFAs & AdCom in July: 📅👇
$Phathom Pharmaceuticals (PHAT.US)$ : 🤔
⇨ VOQUEZNA® (vonoprazan)
‣ Non-Erosive GERD
‣ PDUFA date: 7/19/24 (NDA)
$AstraZeneca (AZN.US)$ : AdCom 🤔
⇨ Imfinzi + chemotherapy
‣ Neoadjuvant treatment NSCLC
‣ AdCom date: 7/25/24(sBLA)
$BeiGene (BGNE.US)$ :...
7
🔥 July: 3 PDUFAs & 1 AdCom
$Arcutis Biotherapeutics (ARQT.US)$ : ARQ-151 topical roflumilast cream
$Phathom Pharmaceuticals (PHAT.US)$ : VOQUEZNA® (vonoprazan)
$AstraZeneca (AZN.US)$ : Imfinzi + chemotherapy - AdCom
$BeiGene (BGNE.US)$ : TEVIMBRA (tislelizumab)
$Arcutis Biotherapeutics (ARQT.US)$ : ARQ-151 topical roflumilast cream
$Phathom Pharmaceuticals (PHAT.US)$ : VOQUEZNA® (vonoprazan)
$AstraZeneca (AZN.US)$ : Imfinzi + chemotherapy - AdCom
$BeiGene (BGNE.US)$ : TEVIMBRA (tislelizumab)
7
2
$AstraZeneca (AZN.US)$ 🥳
📣 Imfinzi + chemotherapy gets approval for endometrial cancer
⇨ Imfinzi (durvalumab) + carboplatin & paclitaxel followed by Imfinzi mono in adult patients w/ primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR)
⇨ based on DUO-E Ph3 trial results 🧬
» showed reduced risk of disease progression or death by 58% 🆚 chemotherapy
📣 Imfinzi + chemotherapy gets approval for endometrial cancer
⇨ Imfinzi (durvalumab) + carboplatin & paclitaxel followed by Imfinzi mono in adult patients w/ primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR)
⇨ based on DUO-E Ph3 trial results 🧬
» showed reduced risk of disease progression or death by 58% 🆚 chemotherapy
6
No comment yet
Ryand83 OP : $ROCHE HOLDING AG (RHHBY.US)$ $AstraZeneca (AZN.US)$
Ryand83 OP : meant to say 40B
not 50B. Point is that Roche would be dummies to screw us over